Ulf Dietrich Kahlert, PhD

2021- now
University Professor Molecular and Experimental Surgery
Otto-von-Guericke University Magdeburg, Germany

2020 Habilitation (Dr. rer. habil.)
Heinrich-Heine University Düsseldorf, Germany

Group Leader “Translational Neurotechnologies” Heinrich-Heine University Düsseldorf, Germany

Post-Doc Fellow, Johns Hopkins Hospital, Baltimore, MD, USA

2012 PhD (Dr.rer. nat.)
Altert-Ludwigs University Freiburg, Germany

>2008 B.Sc./M.Sc. Biology
Gießen, Germany; Brighton, UK; Freiburg, Germany


Professor @ Tiantan Hospital Beijing, PR China

Beijing Tiantan Hospital logo

Tiantan Hospital is a first-in-class research and patient care institution in China, hosting various national forefront medical institutions. It functions as China´s role model for technology inovation in surgical care in the greater Beijing area, featuring AI-driven hospital management, development of high-precision minimally invasive interventional surgery robots, a global first AI-assisted MRI and CT imaging-based diagnosis technology as well as agile clinical trial management to foster, patient-centered, individualzed therapy.
The cooperation is funded by bilateral coopertaion grant from DFG/NSFC.

Elected Expert D.I.N. e.V. / ISO


Since 2019, Professor Kahlert is an accredited expert in the following standardization committees of the German Institute for Standardization (D.I.N. e.V.), a global leader in standardization:

“Biotechnology” (NA 063-09-02 AA)

“Biobanks/ Bioresources” (NA 063-09-02-02 AK)

Professor Kahlert supports the development of reference documents defining norms that are applicable in academic lab environments so that procedures and results present appropriate internal and external validity.

EU COST Action


Vice-Chair of the working group 3, “Preclinical Disease Models”, European Union COST Action 17140 Cancer Nanomedicine “Nano2Clinic”.

Finding efficient cancer therapies is an urgent and still unresolved problem and, in the fight against this disease, scientists are devoting tremendous efforts towards the utilization of nanomedicines. Nanotherapeutics exhibit major benefits with respect to unmodified drugs, including improved half-life, more efficient tumour targeting, and reduced side effects. However, only a few nanotherapeutics have reached the commercial level, most still being in the investigational phase. Accordingly, this Action aims at developing and strengthening industry-academia relations with an ultimate goal: fostering the clinical translation of nanomedicine from bench to bedside.